Oxazepam
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Oxazepam: From Benzodiazepine Anxiolytic/Sedative Use to Insomnia
One-Sentence Summary
Oxazepam is a short/intermediate-acting benzodiazepine; a formal registered original indication was not available in this evidence pack (India/Taiwan market status: not marketed), but its established pharmacological class is anxiolytic/sedative-hypnotic. The TxGNN model predicts it may be effective for Insomnia, with 0 registered clinical trials and 11 supporting publications (including 2 RCTs) currently identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in registry data (no India/Taiwan license on file); pharmacologically classified as a benzodiazepine anxiolytic/sedative-hypnotic |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L3 (literature-based: RCTs, cohort studies, and reviews; no registered clinical trials) |
| India Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Oxazepam is a benzodiazepine that acts at the benzodiazepine binding site on the GABA-A receptor chloride channel, potentiating GABAergic inhibitory neurotransmission. This produces sedative, anxiolytic, and muscle-relaxant effects — a well-characterized sedative-hypnotic mechanism.
Detailed original-indication registry data was not available in this evidence pack (the drug is not currently marketed in India/Taiwan, and 0 licenses are on file), so the original-to-new indication relationship cannot be drawn from regulatory label text. However, based on its known drug class, oxazepam’s core pharmacological action — GABA-A receptor potentiation — is the direct pharmacological basis for hypnotic/sleep-promoting effects. This is consistent with decades of clinical use of benzodiazepines as sleep aids, including direct comparative data (e.g., a 1984 nighttime/daytime efficacy comparison of oxazepam versus flurazepam in chronic insomnia).
Because GABA-A agonism is the established mechanistic pathway for insomnia treatment (rather than an indirect or inferential link), the TxGNN score of 99.86% aligns well with known pharmacology. What remains incomplete is indication-specific registrational evidence: no clinical trials formally studying oxazepam for an insomnia indication are currently registered, and product label safety data (warnings/contraindications) is a blocking data gap.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 6691478 | 1984 | RCT | The American Journal of Psychiatry | In 14 chronic insomnia patients, both oxazepam and flurazepam improved polysomnographic sleep measures; flurazepam caused substantial daytime sleepiness while oxazepam did not, though oxazepam produced some rebound effects |
| 29749262 | 2018 | RCT | The Annals of Pharmacotherapy | Randomized comparison of melatonin vs. oxazepam for anxiety/sleep quality in STEMI patients post-PCI; benzodiazepines effective but with adverse-effect and interaction concerns |
| 17317444 | 2007 | Cohort | Archives of Gerontology and Geriatrics | Study of 60 elderly insomnia patients with comorbidities (depression, dementia, behavioral disturbances) evaluating hypnotic drug effectiveness and safety |
| 6139491 | 1983 | Cohort | JAMA | Withdrawal syndrome observed after substituting a short-acting benzodiazepine (oxazepam) for long-term diazepam use, persisting over a month |
| 29844949 | 2018 | Cohort | PeerJ | Analysis of factors (age, sex, depression, comorbidity) associated with long-term benzodiazepine/z-drug use in older populations |
| 36340306 | 2022 | Review | Journal of Clinical and Experimental Hepatology | Review of alcohol withdrawal syndrome management, where insomnia is a core symptom addressed with sedative-hypnotics in alcoholic liver disease patients |
| 15633073 | 2005 | Review | Psychiatrische Praxis | Cross-sectional review of behavioral/psychological symptoms of dementia (BPSD) management practice, including benzodiazepine/sedative use |
| 23330992 | 2013 | Review | Expert Opinion on Drug Metabolism & Toxicology | Review of anxiolytic drug pharmacokinetics, relevant to benzodiazepine class dosing and sedative effects |
| 23338224 | 1997 | Review | CNS Drugs | Review of paroxetine pharmacology in panic disorder, contextualizing benzodiazepine alternatives for anxiety-related sleep disturbance |
| 39544757 | 2024 | Case Report | American Journal of Translational Research | Case report of a sensory adverse effect with agomelatine, included as related sedative/sleep-agent safety literature |
India Market Information
Oxazepam is not currently registered or marketed in India (0 authorizations on file).
Safety Considerations
- Drug Interactions: A DDI query returned 163 total interactions (sample of 20 detailed below). Notable interactions include:
- Major: Morphine, Morphine (liposomal) — increased CNS/respiratory depression risk
- Moderate: Bupropion, Dronabinol, Nabilone, Metoclopramide, Opium, Sibutramine, Teduglutide
- Minor: Magnesium oxide, Calcium carbonate, Magnesium carbonate, Magnesium hydroxide, Aluminum hydroxide, Magaldrate (antacids — absorption effects)
- Unknown/unclassified: Calcitriol, Glimepiride, Mesalazine, Doxycycline, Clotrimazole
No product label warnings or contraindications data was available in this evidence pack; please refer to the official package insert once obtained.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic link (GABA-A receptor potentiation → sedative-hypnotic effect) is direct and well-established, and literature evidence (including 2 RCTs and multiple cohort studies) supports oxazepam’s sleep-promoting effects. However, no registered clinical trials specifically target an insomnia indication, the drug is not currently marketed in India (0 licenses), and official warnings/contraindications data is a blocking gap (DG001) that prevents a complete S1 safety assessment.
To proceed, the following is needed:
- Official package insert / label data for warnings and contraindications (blocking gap DG001)
- Confirmed original indication and detailed MOA from an authoritative source such as DrugBank (gap DG002)
- Assessment of whether a dedicated Phase 2/3 RCT for insomnia is warranted, given existing evidence is largely older or indirect
- Monitoring protocol addressing major DDIs (notably opioids — Major-level interaction with Morphine) given likely polypharmacy in the target insomnia population (e.g., elderly patients)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.